Concentrations of matrix metalloproteinases and their tissue inhibitors in the cerebrospinal fluid of patients with Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 40, Issue 2, 2014, Pages 351-357

  Mroczko, Barbara ^a   Groblewska, Magdalena ^a   Zboch, Marzena ^b   Kulczyńska, Agnieszka ^a   Koper, Olga M ^a   Szmitkowski, Maciej ^a   Kornhuber, Johannes ^c   Lewczuk, Piotr ^c  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Alzheimer's disease; biomarkers; cerebrospinal fluid; matrix metalloproteinases; tissue inhibitors of matrix metalloproteinases

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; GELATINASE A; GELATINASE B; PROTEIN; PTAU181 PROTEIN; STROMELYSIN; TAU PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA-PROTEIN (1-42); MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; PEPTIDE FRAGMENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD CEREBROSPINAL FLUID BARRIER; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COGNITIVE DEFECT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DEMENTIA; DIAGNOSTIC PROCEDURE; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MILD COGNITIVE IMPAIRMENT; NERVE DEGENERATION; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; MIDDLE AGED; PUNCTURE; RETROSPECTIVE STUDY;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE INHIBITORS; MATRIX METALLOPROTEINASES; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; PEPTIDE FRAGMENTS; RETROSPECTIVE STUDIES; SPINAL PUNCTURE; TAU PROTEINS;

EID: 84901930783     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-131634     Document Type: Article

References (40)

1. Visse R, Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92, 827-839. (Pubitemid 36542523)
2. Huppertz B,Kertschanska S, DemirAY, Frank HG, Kaufmann P (1998) Immunohistochemistry of matrix metalloproteinases (MMP), their substrates, and their inhibitors (TIMP) during trophoblast invasion in the human placenta. Cell Tissue Res 291, 133-148. (Pubitemid 28081574)
3. Rosenberg GA (2009) Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol 8, 205-216.
4. Yong VW, Power C, Forsyth P, Edwards DR (2001) Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2, 502-511. (Pubitemid 33676585)
5. Gardner J, Ghorpade A (2003) Tissue inhibitor of metalloproteinase (TIMP)-1: the TIMPed balance of matrix metalloproteinases in the central nervous system. J Neurosci Res 74, 801-806. (Pubitemid 37490412)
6. Moore CS, Crocker SJ (2012) An alternate perspective on the roles of TIMPs and MMPs in pathology. Am J Pathol 180, 12-16.
7. Cunningham LA, Wetzel M, Rosenberg GA (2005) Multiple roles for MMPs and TIMPs in cerebral ischemia. Glia 50, 329-339. (Pubitemid 40780839)
8. Bjerke M, Zetterberg H, Edman A°, Blennow K, Wallin A, Andreasson U (2011) Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease. J Alzheimers Dis 27, 665-676.
9. Lorenzl S, Buerger K, Hampel H, Beal MF (2008) Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia. Int Psychogeriatr 20, 67-76. (Pubitemid 350256061)
10. Horstmann S, Budig L, Gardner H, Koziol J, Deuschle M, Schilling C, Wagner S (2010) Matrix metalloproteinases in peripheral blood and cerebrospinal fluid in patients with Alzheimer's disease. Int Psychogeriatr 22, 966-972.
11. Deb S, Gottschall PE (1996) Increased production of matrix metalloproteinases in enriched astrocyte and mixed hippocampal cultures treated with beta-amyloid peptides. J Neurochem 66, 1641-1647. (Pubitemid 26090566)
12. Deb S, Wenjun Zhang J, Gottschall PE (2003) Beta-amyloid induces the production of active, matrix-degrading proteases in cultured rat astrocytes. Brain Res 970, 205-213. (Pubitemid 36423196)
13. Stomrud E, Bj?orkqvist M, Janciauskiene S, Minthon L, Hansson O (2010) Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease. Alzheimers Res Ther 2, 20-27.
14. Mlekusch R, Humpel C (2009) Matrix metalloproteinases- 2 and -3 are reduced in cerebrospinal fluid with low betaamyloid1- 42 levels. Neurosci Lett 466, 135-138.
15. Backstrom JR, Lim GP, Cullen MJ, T?ok'es ZA (1996) Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloidbeta peptide (1-40). J Neurosci 16, 7910-7919. (Pubitemid 26405054)
16. Hern'andez-Guillamon M, Delgado P, Ortega L, Pares M, Rosell A, Garć?a-Bonilla L, Fern'andez-Cadenas I, Borrell-Pages M, Boada M, Montaner J (2009) Neuronal TIMP-1 release accompanies astrocytic MMP-9 secretion and enhances astrocyte proliferation induced by beta-amyloid 25- 35 fragment. J Neurosci Res 87, 2115-2125.
17. Peress N, Perillo E, Zucker S (1995) Localization of tissue inhibitor of matrix metalloproteinases in Alzheimer's disease and normal brain. J Neuropathol Exp Neurol 54, 16-22.
18. Adair JC, Charlie J, Dencoff JE, Kaye JA, Quinn JF, Camicioli RM, Stetler-Stevenson WG, Rosenberg GA (2004) Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease. Stroke 35, e159-e162.
19. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging- Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 263-269.
20. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 270-279.
21. Lewczuk P, Zimmermann R, Wiltfang J, Kornhuber J (2009) Neurochemical dementia diagnostics: A simple algorithm for interpretation of the CSF biomarkers. J Neural Transm 116, 1163-1167.
22. Mroczko B, Groblewska M, Barcikowska M (2013) The role of matrix metalloproteinases and tissue inhibitors of metalloproteinases in the pathophysiology of neurodegeneration: a literature study. J Alzheimers Dis 37, 273-283.
23. Yan P, Hu X, Song H, Yin K, Bateman RJ, Cirrito JR, Xiao Q, Hsu FF, Turk JW, Xu J, Hsu CJ, Holtzman DM, Lee JM (2006) Matrix metalloproteinase-9 degrades amyloid- fibrils in vitro and compact plaques in situ. J Biol Chem 281, 24566- 24574. (Pubitemid 44274231)
24. YoshiyamaY, Asahina M, Hattori T (2000) Selective distribution of matrix metalloproteinase-3 (MMP-3) in Alzheimer's disease brain. Acta Neuropathol 99, 91-95. (Pubitemid 30093413)
25. Van Hove I, Lemmens K, Van de Velde S, Verslegers M, Moons L (2012) Matrix metalloproteinase-3 in the central nervous system: A look on the bright side. J Neurochem 123, 203-216.
26. OgataY, Enghild J, NagaseH(1992) Matrixmetalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem 267, 3581-3584.
27. N?ubling G, Levin J, Bader B, Israel L, B?otzel K, Lorenzl S, Giese A (2012) Limited cleavage of tau with matrixmetalloproteinase MMP-9, but not MMP-3, enhances tau oligomer formation. Exp Neurol 237, 470-476.
28. Asahina M, Yoshiyama Y, Hattori T (2001) Expression of matrix metalloproteinase-9 and urinary-type plasminogen activator in Alzheimer's disease brain. Clin Neuropathol 20, 60-63. (Pubitemid 32234485)
29. Van den Steen PE, Dubois B, Nelissen I, Rudd PM, Dwek RA, Opdenakker G (2002) Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol 37, 375-536. (Pubitemid 36071972)
30. Lewczuk P, Popp J, Lelental N, K?olsch H, Maier W, Kornhuber J, Jessen F (2012) Cerebrospinal fluid soluble amyloid- protein precursor as a potential novel biomarkers of Alzheimer's disease. J Alzheimers Dis 28, 119-125.
31. Lewczuk P, Kornhuber J (2011) Neurochemical dementia diagnostics in Alzheimer's disease: where are we now and where are we going? Expert Rev Proteomics 8, 447-458.
32. Lewczuk P, Kornhuber J, Vanmechelen E, Peters O, Heuser I, Maier W, Jessen F, B?urger K, Hampel H, Fr?olich L, Henn F, Falkai P, R?uther E, Jahn H, Luckhaus Ch, Perneczky R, Schmidtke K, Schr?oder J, Kessler H, Pantel J, Gertz HJ, Vanderstichele H, de Meyer G, Shapiro F, Wolf S, Bibl M, Wiltfang J (2010) Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing. Exp Neurol 223, 366-370.
33. Hansson O, ZetterbergH, Buchhave P, Londos E, BlennowK, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5, 228-234. (Pubitemid 43238346)
34. H?oltt?a M, Hansson O, Andreasson U, Hertze J, Minthon L, N?agga K, Andreasen N, Zetterberg H, Blennow K (2013) Evaluating amyloid- oligomers in cerebrospinal fluid as a biomarker for Alzheimer's disease. PLoS One 8, e66381.
35. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9, 119-128.
36. Bruno MA, Mufson EJ, Wuu J, Cuello AC (2009) Increased matrix metalloproteinase 9 activity in mild cognitive impairment. J Neuropathol Exp Neurol 68, 1309-1318.
37. Li W, Poteet E, Xie L, Liu R, Wen Y, Yang SH (2011) Regulation of matrix metalloproteinase 2 by oligomeric amyloid - protein. Brain Res 1387, 141-148.
38. Lim NK, Villemagne VL, Soon CP, Laughton KM, Rowe CC, McLean CA, Masters CL, Evin G, Li QX (2011) Investigation of matrix metalloproteinases, MMP-2 and MMP-9, in plasma reveals a decrease of MMP-2 in Alzheimer's disease. J Alzheimers Dis 26, 779-786.
39. Lorenzl S, Albers DS, Relkin N, Ngyuen T, Hilgenberg SL, Chirichigno J, Cudkowicz ME, Beal MF (2003) Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease. Neurochem Int 43, 191-196. (Pubitemid 36422625)
40. Zimmermann R, Beck G, Knispel S, Maler JM, Weih M, Wiltfang J, Kornhuber J, Lewczuk P (2010) Intrathecal IgG synthesis in patients with alterations in the neurochemical dementia diagnostics. J Alzheimers Dis 19, 1199-1203.